As filed with the Securities and Exchange Commission on March 8, 2017

Registration No. 333-           

 

                                               

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

 

FLEX PHARMA, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

46-5087339

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

800 Boylston Street, 24th Floor
Boston, MA

 

02199

(Address of Principal Executive Offices)

 

(Zip Code)

 

 

2015 Equity Incentive Plan

2015 Employee Stock Purchase Plan

(Full titles of the plans)

 

 

Christoph Westphal, M.D., Ph.D.

President and Chief Executive Officer

Flex Pharma, Inc.

800 Boylston Street, 24 th  Floor

Boston, MA 02199

(617) 874-1821

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

 

Lester Fagen

Marc Recht

Jaime Chase

Cooley LLP

500 Boylston Street, 14th Floor

Boston, Massachusetts 02116

(617) 937-2300

 

Robert Hadfield

General Counsel

Flex Pharma, Inc.

800 Boylston Street, 24 th  Floor

Boston, Massachusetts 02199

(617) 874-1821

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large Accelerated filer

 

o

 

Accelerated filer

x

 

 

 

 

 

 

Non-accelerated filer

 

o (Do not check if a smaller reporting company)

 

Smaller reporting company

o

 

 

 

CALCULATION OF REGISTRATION FEE

 

Title of securities
to be registered

 

Amount
to be
registered (1)

 

Proposed
maximum
offering price
per share (2)

 

Proposed
maximum
aggregate
offering price (2)

 

Amount of
registration fee

 

2015 Equity Incentive Plan

Common Stock, $0.0001 par value per share

 

718,823 shares

(3)

$

4.14

 

$

2,975,927.22

 

$

344.91

 

2015 Employee Stock Purchase Plan

Common Stock, $0.0001 par value per share

 

179,705 shares

(4)

$

4.14

 

$

743,978.70

 

$

86.23

 

(1)           Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock (“Common Stock”) that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction that increases the number of the Registrant’s outstanding shares of Common Stock.

(2)           This estimate is made pursuant to Rule 457(h) and Rule 457(c)(1) of the Securities Act solely for purposes of calculating the registration fee.  The offering price per share and aggregate offering price are based upon the average of the high and low prices of the Common Stock on March 3, 2017, as reported on the Nasdaq Stock Market.

(3)           Represents (i) shares of Common Stock that were automatically added to the number of shares authorized for issuance under the Flex Pharma, Inc. 2015 Equity Incentive Plan (the “2015 EIP”) on January 1, 2017 pursuant to an “evergreen” provision contained in the 2015 EIP.  Pursuant to the evergreen provision, on January 1, 2017 the number of shares authorized for issuance under the 2015 EIP automatically increased by an amount equal to 4% of the total number of shares of Capital Stock (as defined in the 2015 EIP) outstanding on December 31, 2016.

(4)           Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the Flex Pharma, Inc. 2015 Employee Stock Purchase Plan (the “2015 ESPP”) on January 1, 2017 pursuant to an “evergreen” provision contained in the 2015 ESPP. Pursuant to such provision, on January 1, 2017 the number of shares authorized for issuance under the 2015 ESPP automatically increased by a number equal to the lesser of: (a) 1% of the total number of shares of Capital Stock outstanding on December 31 th  of the preceding calendar year; (b) 1,000,000 shares of Common Stock; and (c) a number of shares of Common Stock determined by the Registrant’s board of directors that is less than the amount set forth in the foregoing clauses (a) or (b).

 

 

 


 

EXPLANATORY NOTE

 

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 898,528 shares of Common Stock of Flex Pharma, Inc. (the “Registrant”) issuable pursuant to the Flex Pharma, Inc. 2015 Equity Incentive Plan (the “2015 EIP”) and the Flex Pharma, Inc. 2015 Employee Stock Purchase Plan (the “2015 ESPP”).  These additional shares of Common Stock are securities of the same class as other securities for which an original registration statement on Form S-8 (File No. 333-201816) was filed with the Securities and Exchange Commission (the “Commission”) on February 2, 2015.  These additional shares of Common Stock have become reserved for issuance as a result of the operation of the “evergreen” provisions in each of the 2015 EIP and the 2015 ESPP, which provide that the total number of shares subject to such plans will be increased each year pursuant to a specified formula.

 

PART II

 

INCORPORATION OF DOCUMENTS BY REFERENCE

 

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plans is effective.

 

The Registrant previously registered shares of its Common Stock for issuance under the 2015 EIP and the 2015 ESPP under a Registration Statement on Form S-8 filed with the Commission on February 2, 2015 (File No. 333-201816) and on March 18, 2016 (File No. 333- 210283).  Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statement referenced above.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on March 8, 2017.

 

FLEX PHARMA, INC.

 

 

 

By:

/s/ Christoph Westphal

 

 

Christoph Westphal

 

 

President and Chief Executive Officer

 

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Christoph Westphal and John McCabe, and each of them, as his true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him and in his name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

/s/ Christoph Westphal

 

Chief Executive Officer,
President and Chairman of the Board of Directors

 

 

Christoph Westphal

 

(Principal Executive Officer)

 

March 8, 2017

 

 

 

 

 

/s/ John McCabe

 

Chief Financial Officer

 

 

John McCabe

 

(Principal Accounting and Financial Officer)

 

March 8, 2017

 

 

 

 

 

 

 

 

 

 

/s/ Peter Barton Hutt

 

 

 

 

Peter Barton Hutt

 

Member of the Board of Directors

 

March 8, 2017

 

 

 

 

 

 

 

 

 

 

/s/ Jeffrey D. Capello

 

 

 

 

Jeffrey D. Capello

 

Member of the Board of Directors

 

March 8, 2017

 

 

 

 

 

 

 

 

 

 

/s/ Marc Kozin

 

 

 

 

Marc Kozin

 

Member of the Board of Directors

 

March 8, 2017

 

 

 

 

 

 

 

 

 

 

/s/ Roderick MacKinnon, M.D.

 

 

 

 

Roderick MacKinnon, M.D.

 

Member of the Board of Directors

 

March 8, 2017

 

 

 

 

 

 

 

 

 

 

/s/ Robert J. Perez

 

 

 

 

Robert J. Perez

 

Member of the Board of Directors

 

March 8, 2017

 

3


 

/s/ Stuart Randle

 

 

 

 

Stuart Randle

 

Member of the Board of Directors

 

March 8, 2017

 

 

 

 

 

 

 

 

 

 

/s/ John Sculley

 

 

 

 

John Sculley

 

Member of the Board of Directors

 

March 8, 2017

 

 

 

 

 

 

 

 

 

 

/s/ Michelle Stacy

 

 

 

 

Michelle Stacy

 

Member of the Board of Directors

 

March 8, 2017

 

4


 

EXHIBIT INDEX

 

Exhibit
Number

 

Description 

4.1(1)

 

Amended and Restated Certificate of Incorporation of the Registrant.

 

 

 

4.2(2)

 

Amended and Restated Bylaws of the Registrant.

 

 

 

4.3(3)

 

Form of Common Stock Certificate of the Registrant.

 

 

 

5.1     

 

Opinion of Cooley LLP.

 

 

 

23.1   

 

Consent of Ernst & Young, an Independent Registered Public Accounting Firm.

 

 

 

23.2   

 

Consent of Cooley LLP. Reference is made to Exhibit 5.1.

 

 

 

24.1   

 

Power of Attorney. Reference is made to the signature page hereto.

 

 

 

99.2(4)

 

Flex Pharma, Inc. 2015 Equity Incentive Plan.

 

 

 

99.3(5)

 

Flex Pharma, Inc. 2015 Employee Stock Purchase Plan.

 

(1)          Previously filed as Exhibit 3.5 to the Registrant’s Registration Statement on Form S-1 (File No. 333-201276), filed with the Commission on January 13, 2015, and incorporated herein by reference.

(2)          Previously filed as Exhibit 3.7 to the Registrant’s Registration Statement on Form S-1 (File No. 333-201276), filed with the Commission on January 13, 2015, and incorporated herein by reference.

(3)          Previously filed as Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-201276), filed with the Commission on January 13, 2015, and incorporated herein by reference.

(4)          Previously filed as Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-201276), filed with the Commission on January 13, 2015, and incorporated herein by reference.

(5)          Previously filed as Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-201276), filed with the Commission on January 13, 2015, and incorporated herein by reference.

 

5

FLEX PHARMA, INC. (NASDAQ:FLKS)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more FLEX PHARMA, INC. Charts.
FLEX PHARMA, INC. (NASDAQ:FLKS)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more FLEX PHARMA, INC. Charts.